Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.

Scott, Frank I

Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. [electronic resource] - Journal of Crohn's & colitis Jun 2020 - 575-587 p. digital

Publication Type: Journal Article

1876-4479

10.1093/ecco-jcc/jjz212 doi


Adalimumab--therapeutic use
Adult
Algorithms
Antibodies, Monoclonal, Humanized--administration & dosage
Azathioprine--therapeutic use
Biological Products--economics
Colectomy
Colitis, Ulcerative--drug therapy
Cost-Benefit Analysis--statistics & numerical data
Drug Therapy, Combination
Gastrointestinal Agents--administration & dosage
Humans
Immunosuppressive Agents--therapeutic use
Infliximab--therapeutic use
Male
Markov Chains
Models, Economic
Quality-Adjusted Life Years
Tumor Necrosis Factor-alpha--antagonists & inhibitors